GlassScriptPhysician profile
Jennifer Bacher
NPI 1831730878
$5,375.57
in general payments reported to CMS, 2019-2025
24 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $168 · 2022: $924 · 2023: $1,260 · 2024: $1,590 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,820 · Education: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,819.99 |
| Education | $463.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,479.09 | 2021-2025 | Tremfya |
| Abbvie INC. | $613.66 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $516.81 | 2021-2025 | |
| Lilly USA, LLC | $398.81 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $321.51 | 2022-2024 | Sotyktu |
| Incyte Corporation | $281.72 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $268.47 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $242.94 | 2022-2025 | Winlevi, Absorica Ld, Odomzo |
| Ucb, INC. | $234.77 | 2022-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $170.30 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $153.15 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $149.04 | 2023-2025 | Zoryve |
| Strata Skin Sciences, INC. | $109.39 | 2022-2025 | Xtrac |
| Galderma Laboratories, L.P. | $86.49 | 2022-2025 | Nemluvio |
| Amgen INC. | $82.01 | 2022-2025 | Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.92 | 2022-2023 | Spevigo |
| Leo Pharma INC. | $67.74 | 2021-2025 | Spevigo, Adbry |
| Almirall LLC | $22.10 | 2023 | Seysara |
| Mayne Pharma Commercial LLC | $20.96 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.56 | 2025 | Cabtreo, Siliq |
| Biofrontera INC. | $18.23 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Genentech USA, INC. | $16.64 | 2024 | Actemra |
| Organon LLC | $16.15 | 2025 | Vtama |
| Glaxosmithkline, LLC. | $16.11 | 2024 | Ojjaara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bacher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.